Posterior sub-Tenon injection of triamcinolone acetonide as pretreatment for focal laser photocoagulation in diabetic macular edema patients.
OBJECTIVE
To determine whether a posterior sub-Tenon injection of triamcinolone acetonide (TA) before focal photocoagulation is safe and effective in patients with diabetic macular edema.


METHODS
Sixteen eyes of 11 diabetic patients with unresolved diffuse macular edema were treated with a 20-mg sub-Tenon injection of TA 1 to 2 months before focal photocoagulation. Focal photocoagulation was applied only to microaneurysms, and grid laser photocoagulation was not performed. The main outcome measures used were visual acuity (VA), central macular thickness (CMT) determined by optical coherence tomography (OCT), and the fluorescein angiographic appearance of the retina. Patients were followed for at least 6 months.


RESULTS
One month after the sub-Tenon injection of TA, the macular edema was resolved with a significant reduction of the CMT on OCT. VA improved slightly. Subsequent focal photocoagulation of the microaneurysms maintained the significant reduction of CMT for up to 6 months. A significant improvement of VA was observed in 37.5% patients at 6 months, and there was no decrease in VA in any of the patients.


CONCLUSIONS
A 20-mg sub-Tenon TA injection prior to focal laser photocoagulation is a safe and beneficial treatment in patients with diabetic macular edema.
Shima
Chieko
C
Department of Ophthalmology, Kansai Medical University, Moriguchi, Osaka, Japan.
Ogata
Nahoko
N
Department of Ophthalmology, Kansai Medical University, Moriguchi, Osaka, Japan. ogata@takii.kmu.ac.jp.
Minamino
Keizo
K
Department of Ophthalmology, Kansai Medical University, Moriguchi, Osaka, Japan.
Yoshikawa
Tadanori
T
Department of Ophthalmology, Kansai Medical University, Moriguchi, Osaka, Japan.
Matsuyama
Kayako
K
Department of Ophthalmology, Kansai Medical University, Moriguchi, Osaka, Japan.
Matsumura
Miyo
M
Department of Ophthalmology, Kansai Medical University, Hirakata, Osaka, Japan.
D000368:Aged; D003131:Combined Modality Therapy; D003238:Connective Tissue; D003930:Diabetic Retinopathy / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D005260:Female; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D017075:Laser Coagulation; D008269:Macular Edema / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012160:Retina / Q000473:pathology; D041623:Tomography, Optical Coherence; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000627:therapeutic use*; D014792:Visual Acuity / Q000502:physiology
D005938:Glucocorticoids; D014222:Triamcinolone Acetonide
Ophthalmology. 2005 Jun;112(6):1086-91
15885789
Jpn J Ophthalmol. 2005 Nov-Dec;49(6):509-515
16365798
Ophthalmology. 2004 Feb;111(2):218-24; discussion 224-5
15019365
Ophthalmology. 2007 Jun;114(6):1190-6
17544778
Ophthalmology. 1987 Jul;94(7):761-74
3658348
Br J Ophthalmol. 2007 Apr;91(4):449-54
17077114